Diagnostic Trials
| ClinicalTrials.gov Identifier: |
NCT01786590 |
This study is currently recruiting participants
Ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a novel, minimally invasive modality that enables the assessment of mediastinal and hilar lymph nodes with a high sensitivity. Accurate lymph node staging by EBUS-TBNA will allow opportunities for high-risk patients with lung cancer to undergo minimally invasive treatment.
Ontario
University Health Network
| ClinicalTrials.gov Identifier: |
NCT02906943 |
This study is currently recruiting participants
Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient. Certain drugs are now being developed that target specific molecules in the body that are believed to be part of the disease.
Biomarkers are specific characteristics of the cancer that may help provide prognostic information (e.g. how well patients will be regardless of the treatments given) or help predict sensitivity or resistance to a specific treatment.
The study will collect archival tumor samples (previously collected biopsy or surgical tumor samples) to provide biomarker data about a patient's cancer, which may help their physicians to identify which clinical trials of new drug treatments may be most appropriate for the patient in the future and may also guide the use of approved treatments that may potentially benefit the patient.
Another goal of this study is to develop a province-wide registry of targeted gene sequencing testing results that will be made available to cancer researchers. Additional tumour tissue and blood samples collected from all study participants will also be stored in a biobank at the Ontario Institute for Cancer Research for future research.
The study will also look at linking data from this study to other health care databases to further collect information about the health care the patients received, including medical tests, clinic visits, or procedures both before and after participating in this study. Having more information about patient health to relate to the DNA sequences may provide new insights into cancer and its treatment.
Ontario
Juravinski Cancer Centre, Hamilton
Kingston General Hospital, Kingston
London Health Sciences Centre, London
The Ottawa Hospital, Ottawa
Contact: Han (Jenny) Zhang 613-737-7700 ext 77265
[email protected]
Contact: Kendra Christink 613-737-7700 ext 70308
[email protected]
Principal Investigator: John Hilton, MD
Princess Margaret Hospital, Toronto
Contact: Samantha Del Rossi 416-946-4501 ext 3638
[email protected]
Principal Investigator: Philippe Bedard, MD
Principal Investigator: Lillian Siu, MD
Mount Sinai Hospital, Toronto
Sunnybrook Health Sciences Centre, Toronto
| ClinicalTrials.gov Identifier: |
NCT03702309 |
This study is currently recruiting participants
The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the University Health Network's Princess Margaret Cancer Centre. Circulating cell-free nucleic acids (cfNA), including cell-free DNA (cfDNA) and cell-free RNA (cfRNA), are non-invasive, real-time biomarkers that can provide diagnostic and prognostic information before cancer diagnosis, during cancer treatment, and at disease progression. Cancer research scientists and clinicians at the Princess Margaret are interested in incorporating the collection of peripheral blood samples ("liquid biopsies") into research protocols as a means of non-invasively assessing tumor progression and response to treatment at multiple time points during a patient's course of disease.
Ontario
Princess Margaret Hospital, Toronto
Principal Investigator: Lillian Siu, MD
| ClinicalTrials.gov Identifier: |
NCT04564079 |
This study is currently recruiting participants
A Multi-centre Observational Study to Evaluate the Clinical Utility of Returning Genomic Aberration results Using the Oncomine Precision Assay in Advanced or Metastatic Non-Small Cell Lung Cancer Patients within the Exactis Network
New Brunswick
Moncton
Nova Scotia
Halifax
Ontario
Ottawa
Toronto
Quebec
Montreal
Sherbrooke
| ClinicalTrials.gov Identifier: |
NCT01487603 |
This study is currently recruiting participants
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) samples obtained during diagnosis of lung cancer can be used for molecular analysis that will predict response to treatment and prognosis. In this study, we will detect specific target molecules related to the effectiveness of treatment (surgery, chemotherapy, radiotherapy) and prognosis in patients with lung cancer using EBUS-TBNA samples and its combined with xenograft technology.
Ontario
University Health Network
| ClinicalTrials.gov Identifier: |
NCT02701699 |
This study is currently recruiting participants
The purpose of this study is to look for low levels of oxygen (hypoxia) in lung cancer using a positron emission tomography (PET) scan. Hypoxia can influence how lung cancer grows and responds to treatments like radiotherapy and chemotherapy. The use of PET scans to measure hypoxia may be better and simpler than the approaches used previously. This study will assess whether or not PET scans can provide useful information about hypoxia in lung cancer.
In this study, a radiotracer called Fluoroazomycin Arabinoside (FAZA) will be used to measure hypoxia in the patient's tumour. FAZA has already been used in many cancers including lung cancer. Patients who consent to participate in this trial will receive 1 FAZA PET Scan prior to their first radiotherapy treatment
Ontario
University Health Network, Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9
| ClinicalTrials.gov Identifier: |
NCT01595074 |
This study is not yet recruiting participants.
This research trial studies biomarkers in predicting treatment response in samples from patients with early-stage non-small cell lung cancer previously treated with adjuvant chemotherapy. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related tocancer. It may also help doctors predict how patients will respond to treatment.
Ontario
National Cancer Institute of Canada Clinical Trials Group
Kingston, Ontario, Canada, K7L 3N6
Contact: Lesley K. Seymour 613-533-6430
[email protected]
Principal Investigator: Lesley K. Seym
| ClinicalTrials.gov Identifier: |
NCT03389399 |
This study is currently active but not recruiting participants.
This is a single-arm study of patients who plan on starting brigatinib 90 mg QD or brigatinib 90 mg QD x 7 days to brigatinib 180 mg QD. Participants who enroll on this study protocol will either be taking brigatinib in the context of an ongoing clinical trial, or as part of standard of care treatment as licensed by FDA.
Ontario
Princess Margaret Hospital, Toronto
| ClinicalTrials.gov Identifier: |
NCT04863924 |
This study is currently active, but not recruiting participants
This study will assess the utility of liquid biopsy to accelerate the time to treatment for patients with newly diagnosed advanced non-small cell lung cancer, compared to the conventional diagnostic pathway of molecular testing of tumour tissue after imaging and biopsy.
Ontario
Toronto